| Overview |
| bs-4276R-A647 |
| ELAC2 Polyclonal Antibody, ALEXA FLUOR® 647 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Rabbit |
| Specifications |
| ALEXA FLUOR® 647 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ELAC2 |
| 88-190/826 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 60528 |
| Cytoplasm, Nucleus |
| elaC homolog 2; ElaC homolog protein 2; ELC2; Heredity prostate cancer protein 2; HPC2; putative prostate cancer susceptibility protein HPC2/ELAC2; Ribonuclease Z2; RNase Z2; tRNA 3 endonuclease 2; tRNase Z long form; tRNase Z2; Zinc phosphodiesterase ELAC protein 2. |
| ELAC2 is a zinc phosphodiesterase which displays some tRNA 3' processing endonuclease activity. It is thought to be involved in tRNA maturation, acting by removing a 3' trailer from precursor tRNA. ELAC2 also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. A number of allelic variants have been investigated in hereditary prostate cancer. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz